Avacta Group PLC Issue of Equity (6794L)
October 04 2016 - 10:28AM
UK Regulatory
TIDMAVCT
RNS Number : 6794L
Avacta Group PLC
04 October 2016
04 October 2016
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Director Dealing and Issue of Equity
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, announces that application
has been made for 3,235 new ordinary shares of 10p each (the "New
Ordinary Shares") to be admitted to trading on AIM on 10 October
2016 ("Admission").
The New Ordinary Shares have been allotted pursuant to the
purchase by Michael Albin, Non-Executive Director of the Company,
of New Ordinary Shares in accordance with the terms set out in the
Company's announcement of 23 February 2016.
Following Admission, the total number of ordinary shares with
voting rights in issue will be 68,382,517. Shareholders may use
this figure as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Enquiries:
Avacta Group plc Tel: +44 (0) 844
Alastair Smith, Chief Executive 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0) 207
Geoff Nash / Giles Rolls - Nominated 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane - Corporate
Broking
WG Partners Tel: +44 (0) 203
David Wilson 705 9318
Nigel Barnes Tel: +44 (0) 203
Claes Spang 705 9217
www.wgpartners.co.uk
Media Enquiries Tel: +44 (0) 203
FTI Consulting 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial
responsibilities / person closely associated
------- ---------------------------------------------------------------------------
a) Name Michael Albin
------- ----------------------------------- --------------------------------------
2. Reason for the Notification
------- ---------------------------------------------------------------------------
a) Position/status Non - Executive Director
------- ----------------------------------- --------------------------------------
b) Initial notification/Amendment Initial notification
------- ----------------------------------- --------------------------------------
3. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
------- ---------------------------------------------------------------------------
a) Name Avacta Group Plc
------- ----------------------------------- --------------------------------------
b) LEI n/a
------- ----------------------------------- --------------------------------------
4. Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
------- ---------------------------------------------------------------------------
a) Description of Ordinary shares of 10p
the Financial
instrument, type
of instrument
-------
Identification GB00BYYW9G87
code
------- ----------------------------------- --------------------------------------
b) Nature of the As set out in the Company's
transaction announcement of 23 February
2016, on 22 February 2016
Mr Albin entered into a binding
commitment to purchase GBP3,125
of new Avacta shares per quarter
and the New Ordinary Shares
represent his investment for
the period of 1 July 2016
to 30 September.
------- ----------------------------------- --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------------- --------------
96.6 pence 3,235
---------------- --------------
------- ----------------------------------- --------------------------------------
d) Aggregated information:
* Aggregated volume See above
* Price
------- ----------------------------------- --------------------------------------
e) Date of the transaction 4 October 2016
------- ----------------------------------- --------------------------------------
f) Place of the London Stock Exchange, AIM
transaction Market (XLON)
------- ----------------------------------- --------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEUSUSRNVARRAA
(END) Dow Jones Newswires
October 04, 2016 10:28 ET (14:28 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024
